DETRAXI INC
TAMPA, FLORIDA

We are actively developing innovative solutions to deliver improved patient outcomes. Our aim is to be a leader in transformative healthcare solutions. We are driving the research and development of new solutions for the benefit of the global healthcare industry. We will drive innovation in all areas that provide benefits and demonstrate our leadership ambition in including preservation of cells and tissue, biopsy, oncology, regenerative technologies and blood replacement across both human and veterinary fields. We look to make available solutions that produce incredible real-world health-care outcomes. These benefits will include more effective solutions and lower cost solutions, both through our own efforts and working in collaboration with healthcare providers and technology companies. We want to make a real difference and will always focus our efforts on solutions and markets where we have the innovation power and scale necessary to compete effectively. Our primary focus in North American but we are looking to expand our business into Europe, Asia, Africa and Latin America. A core part of our business is in the active identification and development of highly innovative new solutions and the foundation for this is our active programme of clinical research work to develop new patented products and close collaboration with our partners on development activities that will deliver significant healthcare benefits. We have a commitment to operating a responsible business and in ensuring a positive culture of inclusiveness that fully supports diversity. We care for our people, look to contribute proactively to our local communities, and to always operate with a high level of integrity and transparency. Our Products Detraxi is an active leader and collaborator in the research, development and commercialisation of unique and highly effective life-saving solutions for both the veterinary and human markets. Our core technologies use non-toxic components and a unique Liposome ‘Nano Carrier’ which is patent protected and recognized globally. Our portfolio of products are broken out into: Our goal when Detraxi was founded was to enhance organ preservation and cell culturing at both room temperature and cryopreservation. As our studies involving cells, tissues and organs proceeded it became clear that our patented technology had far broader applications and led us into developing novel therapies for the well-being of both humans and animals We are also looking to revolutionise existing veterinary care by making the technologies that we’re developing for the human market also available to dramatically improve healthcare outcomes by enabling new and vastly improved treatments. About: Detraxi The Company About Detraxi Our Products We have developed a wide range of products, raging from cell to tissue preservation that works in both room temperature as in cryopreservation. Learn About Our Products To learn about all the latest product updates and company announcements please make sure to visit our news section. Detraxi is truly passionate about developing and bringing to market innovative solutions that result in much improved healthcare outcomes.

KEY FACTS ABOUT DETRAXI INC

Company name
DETRAXI INC
Status
Inactive
Filed Number
P18000024320
FEI Number
38-4067142
Date of Incorporation
March 7, 2018
Home State
FL
Company Type
Domestic for Profit

CONTACTS

Website
http://detraxi.com
Phones
(561) 962-1850

DETRAXI INC NEAR ME

Principal Address
3030 N. Rocky Point Dr,
Ste 150A,
Tampa,
FL,
33607,
US

See Also

Officers and Directors

The DETRAXI INC managed by the two persons from RICHMOND, SURREY TW9 1YD UK, RICHMOND, BC V6Y 3H2 CANADA on following positions: PD, STD

Ranjeev Rai

Position
PD Active
From
RICHMOND, SURREY TW9 1YD UK, ,

Abhishek Choudhary

Position
STD Active
From
RICHMOND, BC V6Y 3H2 CANADA, ,





Registered Agent is NORTHWEST REGISTERED AGENT LLC.

Address
3030 N. ROCKY POINT DR, TAMPA, FL, 33607

Events

September 27, 2024
ADMIN DISSOLUTION FOR ANNUAL REPORT
August 17, 2018
AMENDMENT

Annual Reports

2023
January 19, 2023
2022
February 17, 2022